Sprint Bioscience AB

Sprint Bioscience AB

0.35
EUR
0.00
(0.00%)
0.06EPS
5.69P/E
38.83MMarket Cap
Feb 11Next Earn

Total Valuation

EUR

As of June 30, 2026, Sprint Bioscience AB carries a market capitalization of 38.83M, placing it among publicly traded companies globally. Its enterprise value stands at 30.41M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap38.83M
Enterprise Value30.41M

Important Dates

Sprint Bioscience AB's next confirmed earnings release is scheduled for February 11, 2027.

Earnings Date2/11/2027

Share Statistics

As of June 30, 2026, Sprint Bioscience AB has 105.52M shares outstanding.

Shares Outstanding105.52M

Valuation Ratios

As of June 30, 2026, Sprint Bioscience AB trades at a trailing price-to-earnings ratio of 5.69. The price-to-sales ratio is 3.09, and the price-to-book ratio stands at 4.77.

PE Ratio5.69
PS Ratio3.09
PB Ratio4.77
P/TBV Ratio4.77
P/FCF Ratio6.37
P/OCF Ratio6.32

Enterprise Valuation

As of June 30, 2026, Sprint Bioscience AB trades at an EV/EBITDA multiple of 4.25 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.42 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 4.31 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Sprint Bioscience AB trades at an EV/FCF ratio of 4.64, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 30.41M versus a market cap of 38.83M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales2.42
EV / EBITDA4.25
EV / EBIT4.31
EV / FCF4.64

Financial Position

As of June 30, 2026, Sprint Bioscience AB maintains a current ratio of 7.09, meaning it holds 7.1x the short-term assets needed to cover near-term liabilities.

Current Ratio7.09
Quick Ratio6.57
Interest Coverage15.60

Financial Efficiency

EUR

Over the twelve months ended June 30, 2026, Sprint Bioscience AB posted a return on equity (ROE) of 144.94, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 149.87 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 105.90, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 154.68, useful for judging operating efficiency across full business cycles. The company generates approximately 392,579.49 in revenue per employee across its workforce of 32.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)144.94
Return on Assets (ROA)105.90
Return on Invested Capital (ROIC)149.87
Return on Capital Employed (ROCE)154.68
Revenue Per Employee392,579.49
Employee Count32.00

Stock Price Statistics

EUR

As of the close on November 17, 2026, Sprint Bioscience AB's stock has gained approximately 461.09% over the past 52 weeks. The 50-day moving average sits at 0.31, while the 200-day moving average is 0.29.

52-Week Price Change461.09%
50-Day Moving Average0.31
200-Day Moving Average0.29

Income Statement

EUR

Over the twelve months ended June 30, 2026, Sprint Bioscience AB generated 12.56M in revenue and converted that into 6.83M in net income, yielding earnings per share of 0.06. EBITDA reached 7.16M, while operating income came in at 7.06M.

Revenue12.56M
Gross Profit11.90M
Operating Income7.06M
Pretax Income6.83M
Net Income6.83M
EBITDA7.16M
EBIT7.06M
Earnings Per Share (EPS)0.06

Balance Sheet

EUR

These figures are as of June 30, 2026. Total book value stands at 8.13M, with working capital of 7.80M providing operational flexibility.

Cash & Cash Equivalents8.42M
Net Debt-8.42M
Equity (Book Value)8.13M
Book Value Per Share0.08
Working Capital7.80M

Cash Flow

EUR

Sprint Bioscience AB produced 6.14M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -45,592.68 in capital expenditures, free cash flow totaled 6.10M - equivalent to 0.06 per share.

Operating Cash Flow6.14M
Capital Expenditures-45,592.68
Free Cash Flow6.10M
FCF Per Share0.06

Margins

Over the twelve months ended June 30, 2026, Sprint Bioscience AB posted a gross margin of 94.71, reflecting its pricing power and cost economics. The operating margin of 56.22 and net profit margin of 54.37 provide insight into operational efficiency.

Gross Margin94.71
Operating Margin56.22
Pretax Margin54.37
Profit Margin54.37
EBITDA Margin57.00

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 15.70, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -0.03, meaning Sprint Bioscience AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-0.03
FCF Yield15.70

Stock Splits

Sprint Bioscience AB's most recent stock split took place on April 3, 2025.

Last Split Date4/3/2025

Scores

As of June 30, 2026, Sprint Bioscience AB has an Altman Z-Score of 20.18, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score20.18